Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 3:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,608 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Washout Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe

NCT06050291
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
Fixed-Dose Combination (FDC) Tablet
Drug
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Sep 3, 2026, 3:50 AM EDT
Completed Not applicable Interventional

Evaluation of the OtoBand in Subjects With Self-reported Vertigo to Reduce Severity of Vertigo in a Real-world Setting

NCT04869020
View directory record Official record
Conditions
Vertigo
Interventions
Otoband, Sham A, Sham B
Device
Lead sponsor
Otolith Labs
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Sep 3, 2026, 3:50 AM EDT
Completed Phase 3 Interventional

Optimizing Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome (OPTimize NOW): A Symptom-Based Dosing Approach

NCT05980260
View directory record Official record
Conditions
Neonatal Opiate Withdrawal Syndrome
Interventions
Symptom-based Dosing Approach, Scheduled Opioid Taper Approach
Other
Lead sponsor
HELP for NOWS Consortium
Network
Eligibility
1 Hour to 48 Hours
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
23
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Wilmington, Delaware + 16 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 3, 2026, 3:50 AM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Nebivolol Versus Metoprolol in Hypertensive Subject Taking Amlodipine

NCT03635125
View directory record Official record
Conditions
JNC 7 Stage 1 or 2 Hypertension
Interventions
Nebivolol I, Nebivolol II, Baseline Washout Phase
Drug · Other
Lead sponsor
Trinity Hypertension & Metabolic Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Carrollton, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2018 · Synced Sep 3, 2026, 3:50 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion

NCT04459338
View directory record Official record
Conditions
Healthy
Interventions
Exendin-9,39, Saline
Biological · Other
Lead sponsor
Adrian Vella
Other
Eligibility
25 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Sep 3, 2026, 3:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Soticlestat Tablets in Healthy Adults

NCT05284760
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Soticlestat
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Sep 3, 2026, 3:50 AM EDT
Withdrawn Not applicable Interventional

Pharmacodynamic Study on Efficacy of Clopidogrel With St. John's Wort

NCT01330589
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Placebo, St. Johns Wort
Drug
Lead sponsor
Lancaster General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 3, 2026, 3:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Bioequivalence Study on Vitamin C in Healthy Adults

NCT03562988
View directory record Official record
Conditions
Dietary Exposure
Interventions
Vitamin C gummy, Vitamin C tablet
Dietary Supplement
Lead sponsor
Church & Dwight Company, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 22, 2021 · Synced Sep 3, 2026, 3:50 AM EDT
Completed Phase 1 Interventional Results available

Development of Pregnenolone as a Treatment for Depression

NCT03645096
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Pregnenolone 500 mg, Pregnenolone 800 mg, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Sep 3, 2026, 3:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Network-Level Mechanisms for Preclinical Alzheimer's Disease Development

NCT03461861
View directory record Official record
Conditions
APOE 4
Interventions
AGB101 220 mg, Placebo
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
55 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 3, 2026, 3:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Tolerability of Modafinil for Methamphetamine Dependence

NCT00569374
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Modafinil
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2010 · Synced Sep 3, 2026, 3:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants

NCT04933682
View directory record Official record
Conditions
Healthy
Interventions
ALXN2050, Fluconazole, Rifampin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 3, 2026, 3:50 AM EDT
Completed Phase 2 Interventional Results available

Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease

NCT00934362
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Lucinactant first, Placebo first
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
14 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Sep 3, 2026, 3:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of JNJ-42165279 in Healthy Japanese Male Participants

NCT03564379
View directory record Official record
Conditions
Healthy
Interventions
JNJ-42165279, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
20 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 3, 2026, 3:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Delefilcon A and Senofilcon A Daily Disposable Toric Soft Contact Lenses Over One Week of Wear

NCT06749496
View directory record Official record
Conditions
Astigmatism
Interventions
Test Lens, Control Lens
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 39 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
12
States / cities
Jacksonville, Florida • Longwood, Florida • Maitland, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 3, 2026, 3:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes

NCT02513940
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Testosterone, Progesterone, Placebo, Ibutilide
Drug
Lead sponsor
Indiana University
Other
Eligibility
65 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 3, 2026, 3:50 AM EDT
Terminated Phase 2Phase 3 Interventional

Lamictal in the Treatment of Post-Herpetic Neuralgia

NCT00295776
View directory record Official record
Conditions
Neuralgia, Postherpetic
Interventions
Lamictal in the treatment of Post-Herpetic Neuralgia
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 85 Years
Timeline
Started 2005
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2013 · Synced Sep 3, 2026, 3:50 AM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Use Muscadine Wine Nutraceuticals to Improve Brain Health, Cognition, and Mental Health

NCT05541887
View directory record Official record
Conditions
Cognitive Performance, Memory, Mood, Anxiety
Interventions
Muscadine Wine Polyphenol, Placebo
Other
Lead sponsor
University of Florida
Other
Eligibility
50 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 3, 2026, 3:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3009104(Baricitinib) for Healthy Subjects

NCT01247350
View directory record Official record
Conditions
Healthy Volunteer
Interventions
LY3009104, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Sep 3, 2026, 3:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers

NCT01463774
View directory record Official record
Conditions
Healthy
Interventions
Treatment A: Canagliflozin tablet, Treatment A: Metformin IR tablets, Treatment B: Canagliflozin/metformin fixed dose combination tablets
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 20, 2012 · Synced Sep 3, 2026, 3:50 AM EDT
Completed Not applicable Interventional

GI Alpha-Gal Study

NCT06268717
View directory record Official record
Conditions
Alpha-Gal Syndrome, Irritable Bowel Syndrome, Diarrhea, Abdominal Pain, Vomiting
Interventions
Ground pork containing alpha-gal, Pork meat not containing alpha-gal
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 3, 2026, 3:50 AM EDT
Terminated Phase 2 Interventional

Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma

NCT04946318
View directory record Official record
Conditions
Asthma
Interventions
CSJ117, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Bakersfield, California • Huntington Beach, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Sep 3, 2026, 3:50 AM EDT
Completed Phase 3 Interventional Results available

Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients

NCT02770807
View directory record Official record
Conditions
Nervous System Disease, Genetic Syndrome
Interventions
EryDex Low dose DSP, EryDex High dose DSP, Pooled Placebo
Drug
Lead sponsor
Quince Therapeutics S.p.A.
Industry
Eligibility
6 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Sep 3, 2026, 3:50 AM EDT
Completed Phase 2 Interventional Results available

Zinc to Treat Tinnitus in the Elderly

NCT00683644
View directory record Official record
Conditions
Tinnitus
Interventions
Zinc, Placebo oral capsule
Drug
Lead sponsor
University of Iowa
Other
Eligibility
60 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 3, 2026, 3:50 AM EDT